GROWTH OPPORTUNITIES IN MICROBIOME THERAPEUTICS, AI-ENABLED DIAGNOSTICS, ADVANCED WOUND HEALING, DNA STORAGE, SINGLE CELL ANALYSIS, AND MULTI-OMICS PLATFORMS

GROWTH OPPORTUNITIES IN MICROBIOME THERAPEUTICS, AI-ENABLED DIAGNOSTICS, ADVANCED WOUND HEALING, DNA STORAGE, SINGLE CELL ANALYSIS, AND MULTI-OMICS PLATFORMS

RELEASE DATE
17-Dec-2021
REGION
Global
Research Code: D759-00-27-00-00
SKU: HC03484-GL-TA_26101
$950.00
In stock
SKU
HC03484-GL-TA_26101
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) presents growth opportunities in microbiome therapeutics, AI-enabled diagnostics, advanced wound healing, DNA storage, single cell analysis, and multi-omics platforms.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: DNA storage, enzymatic DNA synthesis, molecular diagnostics, AI-based diagnostics, machine learning, liquid biopsy, clinical decision support, oligonucleotides, DNA synthesis, wound healing, RNA interference, drug delivery, cancer diagnostics, CDI, microbiome therapeutics, microbial consortia, fecal microbiota transplant (FMT), biodegradable polymers, immunoassay, infant gut health, engineered microbes, synthetic biology, personalized health, single-cell analysis, genomics, bioinformatics, drug discovery, AI drug discovery, de novo drug design, lung cancer, proteomics, multiplexed analysis, genotype, phenotype, hemostatic

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • INTELLIGENTIA PLATFORM FOR EARLY PROSTATE CANCER DIAGNOSIS
  • THE INTELLIGENTIA PLATFORM COMBINES IMMUNE SYSTEM, RNA SEQUENCING, AND MACHINE LEARNING ABILITY
  • IMMUNIS.AI—INVESTOR DASHBOARD
  • DNA DATA STORAGE FOR RESEARCH, DATA ARCHIVAL, AND PRODUCT TAGGING
  • HELIXWORKS’ ENZYMATIC DNA SYNTHESIS COULD SERVE FUTURE DATA STORAGE
  • HELIXWORKS—INVESTOR DASHBOARD
  • CLOUD-BASED SOLUTIONS FOR THE CANCER DIAGNOSIS AND MONITORING
  • C2I GENOMICS’ PLATFORM PREDICTS CANCER FROM A 2 ML BLOOD SAMPLE MONTHS EARLIER THAN CONVENTIONAL DIAGNOSIS
  • C2I GENOMICS—INVESTOR DASHBOARD
  • AUTOMATED SINGLE-CELL PROTEOMICS ANALYSIS
  • HIGHLY MULTIPLEXED PROTEOMICS WITHIN ONE SYSTEM
  • ISOPLEXIS CORPORATION—INVESTOR DASHBOARD
  • PROBIOTIC SOLUTION FOR INFANT GUT MICROBIOME BALANCE
  • RESTORING DEFICIENT BACTERIA IN INFANTS
  • EVOLVE BIOSYSTEMS—INVESTOR DASHBOARD
  • ADVANCED AI AUGMENTED SINGLE-CELL MULTI-OMICS PLATFORM
  • SINGLE-CELL ANALYSIS SOLUTIONS FOR GENOTYPIC AND PHENOTYPIC ANALYSIS
  • MISSION BIO—INVESTOR DASHBOARD
  • DEFINED MICROBIAL CONSORTIA FOR CDI INFECTION
  • BACTERIAL CONSORTIA AGAINST CDI COLONIZATION
  • VEDANTA BIOSCIENCES—INVESTOR DASHBOARD
  • ENGINEERED MICROBIAL THERAPEUTICS FOR PHENYLKETONURIA
  • EFFICACY COMPARABLE TO SMALL MOLECULE DRUGS
  • SYNLOGIC—INVESTOR LENS
  • FECAL MICROBIOTA TRANSPLANTATION PRODUCT FOR CDI
  • RICH PIPELINE OF CANDIDATES FOR GI CONDITIONS AND BEYOND
  • FINCH THERAPEUTICS—INVESTOR DASHBOARD
  • TAPPING THE GUT MUSCULOSKELETAL AXIS FOR INFLAMMATORY DISEASES
  • MINE NOVEL MICROBIAL STRAINS FOR INFLAMMATORY CONDITIONS
  • SOLAREA BIO- INVESTOR DASHBOARD
  • DEVELOPING CELLULOSE-BASED HEMOSTATIC DRESSING
  • INSTANT SELF-WOUND MANAGEMENT SOLUTION
  • CHITOTECH—INVESTOR DASHBOARD
  • DEVELOPING NOVEL RNA INTERFERENCE THERAPEUTICS AND DELIVERY
  • BUILDING EFFICIENT LIGAND-MEDIATED DELIVERY FOR RNA DRUG DELIVERY
  • ARROWHEAD PHARMACEUTICALS–INVESTOR DASHBOARD
  • DEVELOPING NOVEL NEXT GENERATION PROTEIN THERAPEUTICS
  • ENTERING A NEW ERA OF PROGRAMMABLE PROTEINS
  • GENERATE BIOMEDICINES–INVESTOR DASHBOARD
  • AI INTEGRATED MOLECULAR DIAGNOSTICS FOR LUNG CANCER
  • ASSESSING MINUTE CHANGES IN NON-SMALL CELL LUNG CANCER
  • BIODESIX–INVESTOR DASHBOARD
  • AI PLATFORM FOR DE NOVO DRUG DESIGN AND DEVELOPMENT
  • MULTI-DIMENSIONAL USE OF AI PLATOFRM IN DRUG DISCOVERY
  • XTALPI–INVESTOR DASHBOARD
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) presents growth opportunities in microbiome therapeutics, AI-enabled diagnostics, advanced wound healing, DNA storage, single cell analysis, and multi-omics platforms. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: DNA storage, enzymatic DNA synthesis, molecular diagnostics, AI-based diagnostics, machine learning, liquid biopsy, clinical decision support, oligonucleotides, DNA synthesis, wound healing, RNA interference, drug delivery, cancer diagnostics, CDI, microbiome therapeutics, microbial consortia, fecal microbiota transplant (FMT), biodegradable polymers, immunoassay, infant gut health, engineered microbes, synthetic biology, personalized health, single-cell analysis, genomics, bioinformatics, drug discovery, AI drug discovery, de novo drug design, lung cancer, proteomics, multiplexed analysis, genotype, phenotype, hemostatic
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-27-00-00
Is Prebook No
Ti Codes D759